Journal
PEDIATRIC BLOOD & CANCER
Volume 61, Issue 11, Pages 2115-2117Publisher
WILEY
DOI: 10.1002/pbc.25067
Keywords
angiosarcoma; bevacizumab; KRAS L19F; malignant transformation
Categories
Funding
- NIAMS NIH HHS [R13 AR061943] Funding Source: Medline
Ask authors/readers for more resources
We describe a child initially diagnosed with multi-focal infantile hemangioma (cutaneous, hepatic, pulmonary), a benign vascular lesion, which underwent malignant transformation to angiosarcoma. The use of anti-angiogenic agents, such as bevacizumab, an anti-vascular endothelial growth factor (VEGF) antibody, has been reported in adults with angiosarcoma. Treatment with chemotherapy (gemcitabine and docetaxel) and bevacizumab resulted in disease response with progression free survival of 12 months. This report describes the response to chemotherapy and bevacizumab in a child with angiosarcoma and highlights the potential for malignant transformation of benign vascular lesions and the need for careful monitoring. Pediatr Blood Cancer 2014;61:2115-2117. (c) 2014 Wiley Periodicals, Inc.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available